Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) – Stock analysts at HC Wainwright boosted their Q1 2026 earnings per share (EPS) estimates for shares of Maze Therapeutics in a research report issued on Wednesday, March 25th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.62) per share for the quarter, up from their previous forecast of ($0.73). HC Wainwright currently has a “Buy” rating and a $110.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($2.79) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $1.00 EPS.
Other equities research analysts have also issued reports about the stock. Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Wedbush increased their price objective on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company assumed coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $64.11.
Maze Therapeutics Price Performance
Shares of MAZE stock opened at $30.38 on Friday. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -9.41 and a beta of 4.47. The stock has a 50 day simple moving average of $45.61 and a 200-day simple moving average of $37.77. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $53.65.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.
Institutional Trading of Maze Therapeutics
Several institutional investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics in the 4th quarter valued at about $43,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.
Insider Buying and Selling
In related news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the sale, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $526,119.70. This trade represents a 43.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 245,000 shares of company stock worth $10,504,792.
Maze Therapeutics News Summary
Here are the key news stories impacting Maze Therapeutics this week:
- Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
- Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
- Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
- Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
- Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
- Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
- Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
See Also
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
